The Dermatology Clinical Trials Unit is nationally recognized for developing and participating in clinical therapeutic trials. Clinical trials allow our patients to be exposed to experimental therapeutics. The trials unit is experienced in all areas of dermatologic clinical research from pre-Phase I to Phase IV. We are currently participating in a broad range of clinical trials of novel therapeutics for inflammatory and neoplastic skin disorders. The trials unit draws on the Division of Dermatology’s vast clinical experience.

Dermatology Clinical Trials Unit

Stephanie Farris, Clinical Research Coordinator
Phone: 314-747-8694 Fax: 314-362-6080

Justin Stout, Clinical Research Coordinator
Phone: 314-273-3737 Fax: 314-362-6080

Mary Tabacchi, CRCC, Sr. Clinical Research Coordinator
Phone: 314-362-8171 Fax: 314-362-6080

Milan Anadkat, MD, Director, Clinical Trials Unit 

Currently Enrolling Trials

Dr. Milan Anadkat

*A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab (IL-1 inhibitor) in Patients with Moderate to Severe Hidradenitis Suppurativa

Phase 1, Open-Label, Dose Escalation Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy Study of Topically Administered LUT014 (BRAF agonist) in Metastatic Colorectal Cancer Patients with EGFR Inhibitor Induced Acneiform Lesions

A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 (IL-36R antagonist) in Subjects with Palmoplantar Pustulosis

Dr. Lynn Cornelius

PV-10 Intralesional Injection vs Systemic Chemotherapy or Intralesional Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

Dr. Heather Jones

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum (Cannabanoid) in Dermatomyositis

Dr. Elizabeth Nieman

*Evaluation of the Pharmacokinetics and Safety of Upadacitinib (JAK-inhibitor) in Pediatric Subjects (ages 2-11) with Severe Atopic Dermatitis

Dr. Ann Martin

A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 (topical CBD oil) in Patients with Moderate Atopic Dermatitis

A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator (apremilast)-Controlled Phase 3 Study with Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 (TYK2 inhibitor) in Subjects with Moderate-to-Severe Plaque Psoriasis

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of GBR 830 (anti-CD134) in Adult Subjects With Moderate-to-Severe Atopic Dermatitis

*A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream (JAK-inhibitor) Followed by an Extension Period in Participants with Vitiligo

Dr. Amy Musiek

Randomized, Double-Blind, Placebo-controlled study of Efficacy, Safety, and Tolerability of Serlopitant (neurokinin inhibitor) for the treatment of Chronic Pruritus of Unknown Origin

SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

Phase 2A, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of PF-06823859 (IFN antagonist) in Adult Subjects with Dermatomyositis

A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms Form of Cutaneous T-Cell Lymphoma (CTCL)

Phase 3 Multicenter, Randomized, Placebo-Controlled Study to Determine the Efficacy of Topical SGX 301 and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma

*A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating te Efficacy and Safety of PF-04965842 (JAK-inhibitor) Co-administered with background medicated topical therapy in Adolescent Participants 12 to <18 years of age with Moderate-to-Severe Atopic Dermatitis